Get the Stockscreener App
1.96
1.01%
-0.02
After Hours:
1.97
0.01
+0.51%
Acumen Pharmaceuticals Inc stock is traded at $1.96, with a volume of 165.63K.
It is down -1.01% in the last 24 hours and up +5.38% over the past month.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
See More
Previous Close:
$1.98
Open:
$1.98
24h Volume:
165.63K
Relative Volume:
0.65
Market Cap:
$118.72M
Revenue:
-
Net Income/Loss:
$-64.86M
P/E Ratio:
-1.75
EPS:
-1.12
Net Cash Flow:
$-55.66M
1W Performance:
-1.75%
1M Performance:
+5.38%
6M Performance:
+68.97%
1Y Performance:
+5.95%
1-Day Range:
$1.94
$2.0506
1-Week Range:
$1.90
$2.14
52-Week Range:
$0.8551
$2.46
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Name
Acumen Pharmaceuticals Inc
Sector
Industry
Phone
617-344-4190
Address
1210-1220 WASHINGTON STREET, NEWTON
Compare ABOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
1.96 | 119.94M | 0 | -64.86M | -55.66M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Citigroup | Buy |
| Jul-26-24 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-20-23 | Resumed | BofA Securities | Buy |
| May-18-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-15-22 | Initiated | BTIG Research | Buy |
| Jun-30-22 | Initiated | H.C. Wainwright | Buy |
| Jan-21-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-26-21 | Initiated | BofA Securities | Neutral |
| Jul-26-21 | Initiated | Credit Suisse | Outperform |
| Jul-26-21 | Initiated | Stifel | Buy |
| Jul-26-21 | Initiated | UBS | Buy |
View All
Acumen Pharmaceuticals Inc Stock (ABOS) Latest News
Jindal Steel And Power Can the turnaround happenDividend Cut Warnings & Rapid Portfolio Investment - bollywoodhelpline.com
ABOS stock touches 52-week low at $1.52 amid market challenges - MSN
Acumen Pharmaceuticals, Inc. (ABOS) AI-Powered Stock Analysis - Meyka
Acumen Pharmaceuticals Earnings Notes - Trefis
Acumen Pharmaceuticals (NASDAQ:ABOS) Upgraded at Wall Street Zen - MarketBeat
New Highs: Is Acumen Pharmaceuticals Inc. stock supported by innovation pipeline2025 Top Gainers & Precise Buy Zone Identification - Улправда
Is Acumen Pharmaceuticals Inc. stock a bargain at current levelsJuly 2025 Macro Moves & Technical Confirmation Alerts - DonanımHaber
Is Acumen Pharmaceuticals Inc. stock supported by innovation pipelineWeekly Risk Summary & Technical Analysis for Trade Confirmation - Улправда
Can Acumen Pharmaceuticals Inc. stock maintain operating margins2025 Sector Review & Risk Managed Investment Strategies - Улправда
Retail Surge: Is Acumen Pharmaceuticals Inc. stock supported by innovation pipeline2025 Pullback Review & Fast Entry Momentum Alerts - Улправда
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Financial Review: Acumen Pharmaceuticals (NASDAQ:ABOS) versus Bolt Biotherapeutics (NASDAQ:BOLT) - Defense World
Acumen Pharmaceuticals (NASDAQ:ABOS) Downgraded to Sell Rating by Wall Street Zen - Defense World
Is Acumen Pharmaceuticals Inc. stock a dividend growth opportunityJuly 2025 Macro Moves & Real-Time Buy Zone Alerts - Newser
Can Acumen Pharmaceuticals Inc. stock hit analyst price targetsJuly 2025 WrapUp & AI Powered Buy/Sell Recommendations - Newser
Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NRXP), Akebia Therapeutics (AKBA) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Acumen presents new research on Alzheimer’s treatment delivery By Investing.com - Investing.com Canada
Acumen Pharmaceuticals (ABOS) Stock Analysis Report | Financials & Insights - Benzinga
Acumen Pharmaceuticals Presents Results on Alzheimer’s Disease at Conference - Yahoo
Acumen and JCR Advance Next-Generation CNS Therapeutics with EBD™ Technology - citybiz
What analysts say about Acumen Pharmaceuticals Inc stockStock Liquidity Analysis & Invest Like A Pro - earlytimes.in
Acumen Pharmaceuticals highlights enhanced brain delivery technology for oligomer-selective antibodies - marketscreener.com
Acumen presents new research on Alzheimer’s treatment delivery - Investing.com
Acumen (NASDAQ: ABOS) reports CTAD results on 15 to 68-fold delivery and ALTITUDE-AD recruitment - Stock Titan
Acumen Pharmaceuticals And 2 Other Penny Stocks Worth Watching - Yahoo Finance
Wall Street analysts’ outlook for Acumen Pharmaceuticals Inc (ABOS) - setenews.com
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives $6.75 Average Target Price from Analysts - Defense World
Is Acumen Pharmaceuticals Inc a good long term investmentTrade Execution Strategies & Big Profit Small Investment - earlytimes.in
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Published on: 2025-11-21 08:02:34 - newser.com
Will Acumen Pharmaceuticals Inc. stock go up soonTrade Risk Assessment & Capital Efficiency Focused Ideas - newser.com
Why Acumen Pharmaceuticals Inc. stock is favored by top institutionsWeekly Trade Summary & Free AI Powered Buy and Sell Recommendations - newser.com
Using data models to predict Acumen Pharmaceuticals Inc. stock movementQuarterly Profit Report & Expert Approved Momentum Ideas - newser.com
How risky is Acumen Pharmaceuticals Inc. stock nowJuly 2025 Catalysts & Risk Controlled Stock Pick Alerts - newser.com
Is Acumen Pharmaceuticals Inc. stock dividend yield sustainableQuarterly Profit Summary & Verified Entry Point Signals - newser.com
Acumen Pharmaceuticals (ABOS) Price Target Decreased by 20.59% to 6.88 - MSN
Can Acumen Pharmaceuticals Inc. rally from current levelsTrade Performance Summary & Fast Exit and Entry Strategy Plans - newser.com
Is Acumen Pharmaceuticals Inc. stock recession proofJuly 2025 Retail & Daily Oversold Bounce Ideas - newser.com
Reversal indicators forming on Acumen Pharmaceuticals Inc. stockJuly 2025 News Drivers & Entry and Exit Point Strategies - newser.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: NRX Pharmaceuticals (NRXP), LifeMD (LFMD) and Hims & Hers Health (HIMS) - The Globe and Mail
Is Acumen Pharmaceuticals Inc. stock attractive for passive investorsQuarterly Trade Summary & Daily Technical Stock Forecast Reports - newser.com
B of A Securities Maintains Acumen Pharmaceuticals (ABOS) Buy Recommendation - Nasdaq
ABOS: B of A Securities Lowers Price Target But Maintains Buy Ra - GuruFocus
Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference - The Manila Times
SR Bancorp (NASDAQ: SRBK) announces $0.05 dividend payable Oct. 15 - Stock Titan
Acumen Pharmaceuticals begins open-label extension for Alzheimer’s drug By Investing.com - Investing.com Canada
Acumen Pharmaceuticals Inc Stock (ABOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):